Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1 T315I

Blood (2021) 138 (Supplement 1): 1482.

https://doi.org/10.1182/blood-2021-150120

Published: 2021

Journal Articles

Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)

Panayiotis Panayiotidis, MD, Gayane Tumyan, Catherine Thieblemont, Vadim V Ptushkin, Ana Marin Niebla, Ramon Garcia-Sanz, Andrey Zaritskey, Steven Le Gouill, MD PhD, Christian Buske, MD, Marlies Van Hoef, Thomas Perretti, Monique S Tomiczek, Anastasios Stathis, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-137087

Published: 2020

Journal Articles

BCR-ABL1+ AML De Novo and CBF-Leukemia at Relapse: Game of Clones

Olga Kulemina, MD, Nadia Siordia, MD, Konstantin Bogdanov, PhD, Julia Alexeeva, MD PhD, Larisa Girshova, MD PhD, Elza Lomaia, MD PhD, Andrey Zaritskey, MD PhD

Blood (2019) 134 (Supplement_1): 5138.

https://doi.org/10.1182/blood-2019-129815

Published: 2019

Journal Articles

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Blood (2019) 134 (Supplement_1): 1638.

https://doi.org/10.1182/blood-2019-127951

Published: 2019

Journal Articles

Social Parameters Are Independent Predictors for Survival in Chronic Myeloid Leukemia

Sergei M. Kulikov, PhD, Anna G Turkina, Prof., MD, Anton Kulikovsky, Olga Lazareva, PhD, Sergey Kutsev, Prof., MD, PhD, Elza Lomaia, MD, Andrey Zaritskey, MD PhD, Anatoly Golenkov, MDProf, Tatiana Pospelova, MD PhD, Satokhin Yuri, MD PhD, Tatiana Konstantinova, MD PhD, Elena N. Parovichnikova, MD PhD, Valeriy G. Savchenko, MD PhD

Blood (2018) 132 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2018-99-114700

Published: 2018

Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Blood (2018) 132 (Supplement 1): 790.

https://doi.org/10.1182/blood-2018-99-116803

Published: 2018

Journal Articles

Primary Analysis of JUMP, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis (N = 2233)

Haifa Kathrin Al-Ali, Lynda Foltz, Giuseppe A. Palumbo, Bruno Martino, Francesca Palandri, PhD MD, Anna Marina Liberati, Philipp Le Coutre, Carmen Garcia-Hernandez, Andrey Zaritskey, Renato Tavares, Martin Griesshammer, Vikas Gupta, MD PhD, Pia Raanani, Pilar Giraldo, PhD, Catherine Bouard, Julian Perez Ronco, Ranjan Tiwari, Francesco Mannelli, Alessandro M. Vannucchi

Blood (2017) 130 (Supplement 1): 4204.

https://doi.org/10.1182/blood.V130.Suppl_1.4204.4204

Published: 2017

Journal Articles

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Anna G Turkina, Prof., MD, Oleg Shukhov, MDPhD, Ekaterina Chelysheva, MDPhD, Irina Nemchenko, MD PhD, Anna Petrova, MD, Anastasiya Bykova, MD, Andrey Zaritskey, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Fedor Novikov, PhD, Veronika Shulgina, PhD MD, Ghermes Chilov, PhD

Blood (2017) 130 (Supplement 1): 895.

https://doi.org/10.1182/blood.V130.Suppl_1.895.895

Published: 2017

Journal Articles

Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study

Veronique Leblond, Guy Cantin, MD, Agostino Cortelezzi, Prof, Wolfgang Knauf, Mourad Tiab, Mehmet Turgut, MD, Andrey Zaritskey, Jean-Louis Merot, Kerstin Trunzer, Susan Robson, Ekaterina Gresko, Stephan Stilgenbauer, MD PhD, Robin Foà, Francesc Bosch

Blood (2017) 130 (Supplement 1): 3015.

https://doi.org/10.1182/blood.V130.Suppl_1.3015.3015

Published: 2017

Journal Articles

Baseline Cytogenetic Response Is a Predictor of Outcome of Third Line 2 nd Generation TKI Treatment in Chronic Phase Chronic Myeloid Leukemia Patients

Natalia Lazorko, MD, Elza Lomaia, MD, Vasily Shuvaev, MD PhD, Irina Martynkevich, Mikhail Fominykh, MD, Anna Silyutina, MD, Katerina Ovsiannikova, Nadia Siordia, MD, Andrey Zaritskey, Elena Machulaytene, MD

Blood (2017) 130 (Supplement 1): 5255.

https://doi.org/10.1182/blood.V130.Suppl_1.5255.5255

Published: 2017

Journal Articles

Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233)

Lynda Foltz, MD FRCP, Giuseppe A. Palumbo, MD, Bruno Martino, MD, Francesca Palandri, MD PhD, Haifa Kathrin Al-Ali, MD, Anna Marina Liberati, MD, Philipp D. Le Coutre, MD, Alessandro M. Vannucchi, MD, Carmen Garcia-Hernandez, MD, Renato Tavares, MD, Martin Griesshammer, MD, Vikas Gupta, MD, Pia Raanani, MD, Pilar Giraldo, MD PhD, Catherine Bouard, Julian Perez Ronco, MD MBA, Sadhvi Khanna, MS, Andrey Zaritskey, MD

Blood (2016) 128 (22): 3107.

https://doi.org/10.1182/blood.V128.22.3107.3107

Published: 2016

Journal Articles

Results of the Phase 3 Study of Lenalidomide Versus Placebo As Maintenance Therapy Following Second-Line Treatment for Patients with Chronic Lymphocytic Leukemia (the CONTINUUM Trial)

Robin Foà, MD, Anna Schuh, MD PhD, Andrey Zaritskey, MD, Sergey Semochkin, MD PhD, David Simpson, MBChB, FRACP, FRCPA, Miklos Egyed, Samuel Vokurka, MD PhD, Jeannine Kassis, MDFRCP, Jennie Zhang, PhD, Brendan Purse, BA, MBA, Asher A. Chanan-Khan, MD

Blood (2016) 128 (22): 230.

https://doi.org/10.1182/blood.V128.22.230.230

Published: 2016

Journal Articles

Survival Outcome of Imatinib Mono Therapy in Chronic Phase Chronic Myeloid Leukemia - a Single Center Experience in Belorus

Janna Kozich, MD, Elza Lomaia, MD PhD, Andrey Zaritskey, MD

Blood (2016) 128 (22): 5452.

https://doi.org/10.1182/blood.V128.22.5452.5452

Published: 2016

Journal Articles

Calreticulin Mutations Variants of ET and PMF Patients Studied in Almazov Medical Research Center Russian Federation

Pavel Butylin, PhD, Natalia Matyuhina, MS, Ekaterina Lisina, MD, Nadia Siordia, MD, Olga Senderova, MD, Elza Lomaia, MD PhD, Andrey Zaritskey, MD

Blood (2016) 128 (22): 5499.

https://doi.org/10.1182/blood.V128.22.5499.5499

Published: 2016

Journal Articles

Rare Case of Alternative Splicing Form Caused By L248V Mutation in CML Patient

Pavel Butylin, PhD, Natalia Matyuhina, MS, Nadia Siordia, MD, Elza Lomaya, MD, Andrey Zaritskey, MD

Blood (2015) 126 (23): 5139.

https://doi.org/10.1182/blood.V126.23.5139.5139

Published: 2015

Journal Articles

Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

Elza Lomaia, MD PhD, Andrey Zaritskey, MD, Vasily Shuvaev, MD, Irina Martynkevich, MD PhD, Mikhail Fominykh, MD, Ekaterina Ovsyannikova, MD, Natalia Lazorko, MD, Natalia Matyuhina, MS, Pavel Butylin, PhD, Elena Machyulaitene, MD, Evgenia Salamatova, MD, Kudrat Abdulkadyrov, MD PhD

Blood (2015) 126 (23): 4051.

https://doi.org/10.1182/blood.V126.23.4051.4051

Published: 2015

Journal Articles

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

Blood (2015) 126 (23): 2780.

https://doi.org/10.1182/blood.V126.23.2780.2780

Published: 2015

Journal Articles

The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia

Markus Pfirrmann, Joerg Hasford, MD, Susanne Saussele, Anna Turkina, Prof., MD, Witold Prejzner, MD, Juan Luis Steegmann, MD, Bengt Simonsson, MD, Andrey Zaritskey, MD, Adriana Colita, MD, Daniela Zackova, MD, Jeroen Janssen, MD, Francisco Cervantes, Karel Indrak, MD, Joelle Guilhot, PhD, Ruediger Hehlmann, MD, Michele Baccarani, MD

Blood (2015) 126 (23): 595.

https://doi.org/10.1182/blood.V126.23.595.595

Published: 2015

Journal Articles

Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242

Anders Österborg, Miklós Udvardy, Andrey Zaritskey, Per-Ola Andersson, Sebastian Grosicki, Grzegorz Mazur, Polina Kaplan, Michael Steurer, Anna Schuh, Marco Montillo, Iryna Kryachok, Jan Moritz Middeke, Yaroslav Kulyaba, Grygoriy Rekhtman, Michele Gorczyca, Siobhan Daly, Chang Chai-Ni, Steen Lisby, Ira Gupta

Blood (2014) 124 (21): 4684.

https://doi.org/10.1182/blood.V124.21.4684.4684

Published: 2014

Journal Articles

Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data

Blood (2014) 124 (21): 3145.

https://doi.org/10.1182/blood.V124.21.3145.3145

Published: 2014

NARROW

PF-114 in Patients Failing Prior Tyrosine Kinase-Inhibitor Therapy Including BCR::ABL1 T315I

Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)

BCR-ABL1+ AML De Novo and CBF-Leukemia at Relapse: Game of Clones

PF-114: A 4 th Generation Tyrosine Kinase-Inhibitor for Chronic Phase Chronic Myeloid Leukaemia Including BCRABL1 T315I

Social Parameters Are Independent Predictors for Survival in Chronic Myeloid Leukemia

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Primary Analysis of JUMP, a Phase 3b, Expanded-Access Study Evaluating the Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis (N = 2233)

PF-114 Mesylate, a Novel Third Generation ATP-Competitive BCR-ABL Tyrosine Kinase Inhibitor: First Safety and Efficacy Data from a Phase I Study in Patients with CML with Failure of Prior TKI Therapy

Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study

Baseline Cytogenetic Response Is a Predictor of Outcome of Third Line 2 nd Generation TKI Treatment in Chronic Phase Chronic Myeloid Leukemia Patients

Safety and Efficacy of Ruxolitinib for the Final Enrollment of JUMP: An Open-Label, Multicenter, Single-Arm, Expanded-Access Study in Patients with Myelofibrosis (N = 2233)

Results of the Phase 3 Study of Lenalidomide Versus Placebo As Maintenance Therapy Following Second-Line Treatment for Patients with Chronic Lymphocytic Leukemia (the CONTINUUM Trial)

Survival Outcome of Imatinib Mono Therapy in Chronic Phase Chronic Myeloid Leukemia - a Single Center Experience in Belorus

Calreticulin Mutations Variants of ET and PMF Patients Studied in Almazov Medical Research Center Russian Federation

Rare Case of Alternative Splicing Form Caused By L248V Mutation in CML Patient

Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia

Treatment and Outcome Analysis of 2,904 Pateints from the EUTOS Population Based Registry

The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia

Ofatumumab (OFA) Vs. Physician’s Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242

Incidence of CML in Europe—a Comparison of 19 European Countries with US SEER Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only